title: Non-Infectious Uveitis: Optimising the Therapeutic Response.
abstract: Non-infectious uveitis mainly affects the working-age population and can contribute to significant social and economic burden. It comprises a heterogeneous group of conditions with varied aetiology. Precise and early diagnosis, excluding masquerade syndromes, is the key to early therapeutic intervention. Treatment should be appropriately selected according to the anatomical sites of inflammation, the diagnosis and known prognosis, and whether there is a systemic inflammatory drive. Corticosteroids in the form of local or systemic therapy form the mainstay of treatment; however, due to unacceptable side effects, the need for long-term use or suboptimal response, corticosteroid-sparing medications may need to be considered early on in the management of non-infectious uveitis. With newer insights into the immunopathology of uveitis and the availability of biologic agents, treatment can be tailored according to individual needs. Many patients have systemic involvement, and hence a multidisciplinary approach is often required to achieve the best outcome in an individual. Patient involvement in the management of non-infectious uveitis, ensuring compliance, and continual monitoring of both the treatment and therapeutic response are the key to achieving optimal outcomes.
authors.affiliation: York Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
authors.forename: Archana
authors.initials: A
authors.lastname: Airody
authors.affiliation: York Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
authors.forename: Greg
authors.initials: G
authors.lastname: Heath
authors.affiliation: Department of Clinical Ophthalmology, Institute of Ophthalmology/Moorfields Eye Hospital, London, UK.
authors.forename: Susan
authors.initials: S
authors.lastname: Lightman
authors.affiliation: York Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK. richard.gale@york.nhs.uk.
authors.forename: Richard
authors.initials: R
authors.lastname: Gale
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011788:Quality of Life; D017211:Treatment Failure; D014605:Uveitis / Q000145:classification / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents